Environmental Conditions May Shape the Patterns of Genomic Variations in Leishmania panamensis by Restrepo, Carlos M. et al.
genes
G C A T
T A C G
G C A T
Article
Environmental Conditions May Shape the Patterns of
Genomic Variations in Leishmania panamensis
Carlos M. Restrepo 1,†, Alejandro Llanes 1,2,† , Eymi M. Cedeño 3, Jim H. Chang 3,
Jennifer Álvarez 4, Margarita Ríos 5, Homero Penagos 6, José A. Suárez 5 and
Ricardo Lleonart 1,*
1 Centro de Biología Celular y Molecular de Enfermedades, Instituto de Investigaciones Científicas y Servicios
de Alta Tecnología (INDICASAT AIP), Panama 0801, Panama; crestrepo@indicasat.org.pa (C.M.R.);
allanes@indicasat.org.pa (A.L.)
2 Department of Biotechnology, Acharya Nagarjuna University, Guntur, Andhra Pradesh 522510, India
3 Departamento de Biotecnología, Facultad de Ciencias de la Salud, Universidad Latina de Panamá,
Panama 0801, Panama; eymicedeno@gmail.com (E.M.C.); jimhc_3193@outlook.com (J.H.C.)
4 Escuela de Biología, Facultad de Ciencias Naturales, Exactas y Tecnología, Universidad de Panamá,
Panama 0801, Panama; jenniferalvarez1412@gmail.com
5 Unidad Clínica de Investigación, Clínica de Medicina Tropical, Instituto Conmemorativo Gorgas de Estudios
de la Salud (ICGES), Panama 0801, Panama; mrios@gorgas.gob.pa (M.R.); jsuarez@gorgas.gob.pa (J.A.S.)
6 Hospital Regional Dr. Rafael Hernández, Caja de Seguro Social, Chiriquí 0401, Panama;
hapenagosg@hotmail.com
* Correspondence: rlleonart@indicasat.org.pa; Tel.: +507-517-0740
† These two authors contributed equally to the article.
Received: 21 August 2019; Accepted: 8 October 2019; Published: 24 October 2019


Abstract: Due to the absence of transcriptional regulation of gene expression in Leishmania parasites,
it is now well accepted that several forms of genomic variations modulate the levels of critical
proteins through changes in gene dosage. We previously observed many of these variations in our
reference laboratory strain of L. panamensis (PSC-1 strain), including chromosomes with an increased
somy and the presence of a putative linear minichromosome derived from chromosome 34. Here,
we compared the previously described genomic variations with those occurring after exposure of
this strain to increasing concentrations of trivalent antimony (SbIII), as well as those present in two
geographically unrelated clinical isolates of L. panamensis. We observed changes in the somy of several
chromosomes, amplifications of several chromosomal regions, and copy number variations in gene
arrays after exposure to SbIII. Occurrence of amplifications potentially beneficial for the Sb-resistant
phenotype appears to be associated with the loss of other forms of amplification, such as the linear
minichromosome. In contrast, we found no evidence of changes in somy or amplification of relatively
large chromosomal regions in the clinical isolates. In these isolates, the predominant amplifications
appear to be those that generate genes arrays; however, in many cases, the amplified arrays have a
notably higher number of copies than those from the untreated and Sb-treated laboratory samples.
Keywords: Leishmania panamensis; genomic variations; antimony resistance
1. Introduction
Leishmania is a kinetoplastid parasite causing several clinical presentations collectively known
as leishmaniasis. The parasite develops as a flagellated promastigote in its sandfly vector and as
an amastigote with a retracted flagellum in the macrophages of its vertebrate hosts. Leishmania
species that are known to be pathogenic to humans are divided into two main subgenera, namely,
L. (Leishmania) and L. (Viannia). Species belonging to the L. (Viannia) subgenus are exclusively present
Genes 2019, 10, 838; doi:10.3390/genes10110838 www.mdpi.com/journal/genes
Genes 2019, 10, 838 2 of 15
in Central and South America and cause mainly cutaneous leishmaniasis. However, in some cases,
the parasites can migrate to the nasopharyngeal area and cause a more severe presentation called
mucocutaneous leishmaniasis. The L. (Viannia) subgenus comprises two major species complexes,
namely the L. braziliensis complex, which also include L. peruviana, and the L. guyanensis complex,
which also include L. panamensis. L. panamensis is the main causative agent of leishmaniasis in Panama
and it is responsible of a significant number of cases in neighboring countries.
As in other kinetoplastids, gene expression in Leishmania is not primarily regulated at the initiation
of transcription, but mainly at the post-transcriptional level by mechanisms that modulate the amounts
of mRNA and its stability [1]. Among these mechanisms, it has been demonstrated that cellular levels
of critical proteins are modulated by changes in gene dosage [2]. These changes are in turn associated
with different types of genomic variations typically involving some form of genetic amplification, such
as the increase in copy number of individual genes to form tandem gene arrays, the amplification of
larger regions in the form of linear or circular extrachromosomal episomes, as well as changes in the
somy of entire chromosomes [3]. Both intra- and extrachromosomal amplifications are largely stochastic
and appear to involve recombination of repetitive elements flanking the region to be amplified [4].
Variations in the somy of individual chromosomes are also stochastic in nature and can occur even in
different individuals within the same population, giving rise to the phenomenon known as mosaic
aneuploidy [5].
Despite their stochastic nature, many of these genomic variations appear to represent an adaptive
advantage for Leishmania parasites. Perhaps the best characterized example are the variations selected
in the presence of pentavalent antimonials [6]. These compounds are pentavalent antimony (SbV)
derivatives that have been used as the first-line treatment for leishmaniasis since the 1940s. After an
obligate reduction step, SbV is converted to trivalent antimony (SbIII) [7], which can kill the parasite
trough mechanisms that are not yet well understood. Genetic changes associated with resistance to
SbIII can appear quickly and transiently, often disappearing when the drug pressure is removed [8].
Different forms of genetic amplifications potentially associated with the acquisition of the Sb-resistant
phenotype have been reported for species of the L. (Leishmania) subgenus, including L. infantum [9],
L. donovani [10–12], and L. major [13], as well as for those belonging to the L. (Viannia) subgenus [14,15].
Variations in chromosome somy were ubiquitously observed in all these studies, but in some cases,
the episomal amplification of relatively large chromosomal regions was also reported. Particularly
relevant in this context is the amplification of a region of chromosome 23, called the H-locus [16],
leading to circular episomes. This region contains at least one gene encoding an ATP-binding cassette
(ABC) transporter known as multidrug resistance protein A (MRPA) or P glycoprotein A (PGPA),
which has long been known to be overexpressed in resistant amastigotes [17,18]. In addition, deletion
of chromosomal regions has also been reported, typically leading to gene loss or to a reduction in copy
number. An example is the deletion of subtelomeric segments of chromosome 31 containing the AQP1
gene, which codes for a specific aquaglyceroporin that imports SbIII into amastigotes [19].
Genomic amplifications have also been observed in Leishmania in absence of drug pressure.
For instance, several types of amplicons deriving from a subtelomeric region of chromosome 34,
called LD1, have been reported in different Leishmania species [20,21]. Since this region contains a
gene encoding a biopterin transporter (BT1), its amplification may be associated with an improved
acquisition of pterins required for folate metabolism. A particular type of LD1 amplification, consisting
of a linear minichromosome of ~245 kb, was initially observed in some strains of L. braziliensis [22]. Later,
we found evidenced of the presence of a similar minichromosome in our reference L. panamensis strain
(strain PSC-1) [23], thus suggesting that this particular type of LD1 amplification may be specific to the
L. (Viannia) subgenus. Here, we aimed to compare the patterns of genomic variations among the PSC-1
strain, an antimony-resistant mutant and two geographically unrelated clinical isolates of L. panamensis.
In order to generate the resistant mutant, we exposed the PSC-1 strain to increasing concentrations of
potassium antimonyl tartrate. Whole genome sequencing (WSG) was performed at seven different SbIII
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concentrations, thus allowing us to characterize not only the genomic variations in the final resistant
mutant but also the dynamics of these variations during acquisition of the resistant phenotype.
2. Materials and Methods
2.1. Ethical Statement
The work in human patients was approved by the ethical board of Hospital Punta Pacífica,
Panama, with approval code FID14-126 No.27 and approval date of October 28, 2015. Although data
were analyzed anonymously, written informed consent was obtained from patients before samples
were taken.
2.2. Clinical Sample Collection
Sample collection was conducted at Instituto Conmemorativo Gorgas de Estudios de la Salud
(ICGES), Panama City, Panama and Hospital Regional Dr. Rafael Hernández, Chiriquí, Panama. ICGES
is the national reference center for clinical diagnosis of leishmaniasis and patients are referred to this
institute from almost all over the country. Children less than six years of age, patients with lesions
indicative of intercurrent bacterial or fungal infection and patients on active treatment for cutaneous
leishmaniasis were excluded from the study. Cutaneous lesions were examined by a specialized
physician for proper identification of the lesion and exclusion of secondary bacterial infection. Lesion
aspirates were collected aseptically using a 25-gauge needle and disposable syringe containing 0.5 mL
of sterile saline, which was inserted intradermally into the active border of the lesion. The syringe
was rotated and tissue fluid was then aspirated into the needle. Aspirated fluid was inoculated into
biphasic medium comprised of a solid phase of blood agar base (Sigma-Aldrich, St. Louis, MO, USA)
supplemented with 50 µg/mL gentamicin (Sigma-Aldrich, St. Louis, MO, USA) and 10% of aseptically
collected defibrinated rabbit blood, and a liquid phase of Schneider’s insect medium (Sigma-Aldrich,
St. Louis, MO, USA) at pH 7.2, supplemented with 20% (v/v) heat-inactivated fetal bovine serum
(Gibco, Gaithersburg, MD, USA) and 50 µg/mL gentamicin. Isolates were incubated at 25 ◦C and
monitored microscopically for 15 days for the presence of promastigotes.
2.3. Parasite Culture and Generation of an Antimony-Resistant L. panamensis Strain
L. panamensis promastigotes were axenically maintained in serum-supplemented Schneider’s insect
medium, prepared as described in the previous section, and incubated at 25 ◦C. The antimony-treated
L. panamensis samples were selected from the wild type PSC-1 strain (MHOM/PA/1994/PSC-1) in 25 cm2
tissue culture flasks containing 10 mL of serum-supplemented Schneider’s medium in the presence of
increasing SbIII concentrations. Potassium antimonyl tartrate (≥ 99% purity) (Sigma-Aldrich, St. Louis,
MO, USA) was used as the source of SbIII. Stepwise drug selection started from 50 µM up to 2000 µM
of SbIII.
2.4. Antimony Susceptibility Assay
Resazurin sodium salt (7-hydroxy-3H-phenoxazin-3-one-10-oxide sodium salt) was employed
for antimony susceptibility assay. Resazurin is a redox indicator that reduces to fluorescent resorufin
as a result of the metabolic activity of cells. Mid-log growth phase promastigotes were diluted in
serum-supplemented Schneider’s medium and seeded in a 96-well black plate (Thermo Scientific, Nunc,
Rochester, NY, USA) at a density of 1 × 106 parasites per well in a final volume of 100 µL. Parasites were
incubated at 25 ◦C during 48 hours in presence or absence of several half-log dilutions of potassium
antimonyl tartrate. After the incubation period, 20 µL of a 0.15 mg/mL solution of resazurin sodium
salt in phosphate-buffered saline (PBS) (Sigma-Aldrich, St. Louis, MO, USA) were added to each well
and the plate was incubated at 25 ◦C for 24 hours. Parasite viability was measured fluorometrically
(λex 560 nm; λem 590 nm) in a multidetection microplate reader (Synergy HT-Biotek, Winooski, VT,
USA) and expressed in relative-fluorescent units (RFU). The assay was performed in triplicates and the
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half maximal effective concentration (EC50) was calculated by adjusting a sigmoidal dose–response
curve using GraphPad Prism version 6.0 (GraphPad Software Inc., San Diego, CA, USA).
2.5. Whole Genome Sequencing
High-quality genomic DNA was extracted from the untreated PSC-1 strain and from the treated
samples at each different SbIII concentration (50, 100, 200, 400, 800, 1600, and 2000 µM SbIII), as well
as from the two clinical isolates. Genomic DNA was extracted from stationary phase promastigotes,
using a commercial salting out procedure as recommended by the manufacturer (Wizard Genomic
DNA purification kit, Promega, Madison, WI, USA). Size, integrity, and presence of contaminants in
the DNA samples were assessed through gel electrophoresis. DNA concentration was estimated by the
picogreen method (Invitrogen, Carlsbad, CA, USA) using Victor 3 fluorometry (PerkinElmer, Waltham,
MA, USA). DNA purity was measured using a NanoDrop 2000 spectrophotometer (Thermo Scientific,
Waltham, MA, USA). Sequencing libraries with 150 bp shotgun (paired-end) reads were prepared from
100 ng of genomic DNA by using the TruSeq Nano sample preparation protocol (Illumina, Inc., San
Diego, CA, USA) and then sequenced in a NovaSeq 6000 instrument for a total throughput of 4 Gb
per sample.
2.6. Estimation of Chromosome Somy
Illumina reads were first normalized to a total of 14 million per sample and trimmed to 100 bp with
Trimmomatic [24]. Reads were aligned to the reference genome by using BWA-MEM [25]. SAMtools
depth (version 0.1.19) [26] was used to record the read depth per base for all chromosomes at the
different SbIII concentrations. Somy of individual chromosomes was estimated by first calculating the
median read depth for each chromosome and then dividing this value by the mode of all calculated
medians, which was expected to correspond to disomic chromosomes. Before computing the median
read depth for each chromosome, all values lying ±3 standard deviations away from the mean were
considered outliers and were further removed in order to avoid inaccurate estimations.
Since it has been suggested that large local variations in read depth [10,27] and chromosome
length [3,10] can both affect somy estimates, we compared our original estimations with those obtained
with the methodology proposed by Dumetz et al. [11]. This methodology is based on the same
principle, but differs in that the median read depth is first computed by dividing each chromosome in
2500 bp bins and the somy estimation is done with a median calculated from its fourteen neighboring
chromosomes, instead of using a single median value for the whole dataset. Statistical significance of
the somy estimates were calculated by using the Mann–Whitney–Wilcoxon (MWW) test performed
with the Statistics::Test::WilcoxonRankSum package from Perl (version 5.16). Samples with a P ≤ 10−5
were considered to be significant. The following ranges were used when assigning a somy to each
chromosome from the corresponding estimates: disomic: ≥1.5, <2.5; trisomic: ≥2.5, <3.5; tetrasomic:
≥3.5, <4.5; pentasomic: ≥4.5, <5.5 and hexasomic: ≥5.5, <6.5.
2.7. Detection of Genetic Amplifications
Local amplifications within chromosomes were identified by using CNVnator [28] with default
parameters. CNVnator results were complemented with manual revision to identify all local peaks
spanning regions larger than 2 kb in the distribution of read depth along each chromosome.
2.8. Detection of Variants Associated with Protein-Coding Genes
Copy number variations (CNVs) associated with protein-coding genes were identified as described
for entire chromosomes, but submitting an additional file to SAMtools with the corresponding
annotations in BED format. The haploid copy number for each gene was then estimated by the
ratio between its median read depth and the median read depth of its corresponding chromosome.
In addition, the Genome Analysis Toolkit (GATK) (version 4.0.11) [29] was used to identify single
nucleotide variants (SNVs) and small insertion/deletions (indels) of up to 3 bp, while SvABA [30] was
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used to identify larger indels and structural variants. For the GATK methodology, we separated the
reads mapping to each chromosome into individual BAM files and submitted them independently to
the UnifiedGenotyper module, so that the somy estimated for each chromosome could be incorporated
as a parameter of the variant calling algorithm.
3. Results
3.1. Generation of an Antimony-Resistant L. panamensis Strain
Antimony resistance was developed in vitro in our reference PSC-1 strain via exposure to increasing
concentrations of potassium antimonyl tartrate. Susceptibility to SbIII was measured through an
indirect fluorescence assay with resazurin. The untreated strain showed an initial EC50 of 212.3 µM
(Figure 1A). This strain was subjected to increasingly higher concentrations of SbIII during a period
of 30 weeks, starting at 50 µM and up to a maximum of 2000 µM. Resistant cultures were selected at
400, 800, 1600, and 2000 µM of SbIII, representing resistance indexes (RI) of 1.88, 3.76, 7.54, and 9.42,
respectively. At each selection point, parasites were grown in the presence of the appropriate SbIII
concentration, during four passages, before DNA extraction and passage to the next SbIII concentration.
The final-stage culture showed an EC50 of 2354 µM (Figure 1B) and retained the resistant phenotype
after 10 passages in absence of antimony.
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In order to compare the findings observed in the laboratory strains, we also included in this study
two L. panamensis clinical samples, isolated from human patients with no record of treatment failure.
The SbIII susceptibility assay for these isolates, named BD-02 and RG-01, revealed EC50 values of
26.58 µM and 5.27 µM, respectively. Surprisingly, both values are notably lower than the initial EC50
measured for our PSC-1 reference strain, suggesting that this laboratory-adapted strain may have a
lower susceptibility than natural isolates, although it does not exhibit a defined Sb-resistant phenotype.
3.2. Variations in Chromosome Somy and Relatively Large Chromosomal Regions
Whole genome sequencing (WGS) was performed for 11 L. panamensis samples, namely, the
untreated PSC-1 strain, the antimony-treated samples collected at seven different SbIII concentrations,
and the clinical isolates BD-02 and RG-01. Sequence data generated in this study was submitted to
the Sequence Read Archive (SRA) and is accessible through BioProject PRJNA558039. Variations in
chromosome somy and in relatively large chromosomal regions were inferred from the distribution
of sequence reads, after mapping them to our L. panamensis reference genome [23]. Chromosome
somy was estimated by first using the mode of the median read depth for all chromosomes and then
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applying the strategy suggested by Dumetz et al. [11], with similar results in both cases (Table S1).
Eleven chromosomes (1, 3, 6, 12, 13, 18, 21, 23, 26, 31, and 32) showed at least one statistically significant
change in somy at a different SbIII concentration during acquisition of the Sb-resistant phenotype, when
compared to the untreated PSC-1 strain (Figure 2A; Table S2). Three of these, in fact, showed a marked
increase in somy apparently correlating with the increase in SbIII concentration, namely, chromosomes
1 and 18 (from a disomic to a tetrasomic state) and chromosome 31 (from a tetrasomic to a hexasomic
state). A singular case is chromosome 23, for which the reference estimate suggested a trisomic state,
but which appears to exist in pentasomic state above 50 µM of SbIII and then in tetrasomic state above
1600 µM. As previously reported for other Leishmania genomes, we obtained several intermediate
somy estimates for certain chromosomes, which are likely to be associated with the phenomenon of
mosaic aneuploidy.
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In contrast to the extensive variation in chromosome somy observed in the laboratory-adapted
strains, even before exposure to SbIII, we found little variation in the clinical isolates (Figure 2B).
In these isolates, almost all chromosomes appear to be in a disomic state, with the notable exception
of chromosome 31, which is in a tetrasomic state. Likewise, the phenomenon of intermediate somy
estimates mentioned above was not detected in these isolates.
In addition to changes in the somy of certain chromosomes, we found evidence of amplification
at several relatively large chromosomal regions in both the untreated reference strain and the treated
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samples (Figure S1, Table S3). Although many of these regions appear to be equally amplified before
and after exposure to SbIII, at least two of them showed different copy number estimates at different
SbIII concentrations (Figure 3). One of these amplifications is located in chromosome 23, overlapping
the region occupied by the H-locus (Figure 3A). This amplification appears to occur at concentrations
above 800 µM of SbIII and spans a region of ~53 kb, comprising 18 protein-coding genes. As expected,
the amplified region contains gene LPMP_230280, coding for ABC transporter MRPA. Interestingly,
the amplified region also appears to have a “nested” amplification of a locus encoding another ABC
transporter of the type C family (LPMP_230230, ABCC), which is probably organized as a tandem
gene array within the H-locus amplicons.
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different SbIII co centrations. (A) Amplification f a region of ~53 kb of chromosome
23 overlapping the H-locus. (B) Region f ~101 kb from chromosome 34, suspected to be
amplified in the form of a linear minichromosome. ABCC: ABC transporter, type C family; ALG11:
α-1,2- annosyltransferase; BT1: biopterin transporter 1; HTBF: H region terbinafine-associated
resistance gene; HUS1: checkpoint protein HUS1; MRPA: multidrug resistance protein A; PTR1:
pteridine reductase 1.
The second differentially amplified region observed in this study is located near one of the
ends of chromosome 34, spanning approximately 101 kb and containing 28 protein-coding genes
(Figure 3B). This amplification is likely to give rise to a linear minichromosome previously reported in
L. braziliensis [22] and L. panamensis [23]. However, this minichromosome is only apparently present at
SbIII concentrations between 0 and 100 µM, with no evidence of amplification at higher concentrations.
We found no evidence of the pres nce of this minichromosome or the H-locus amplification in the
clinical isolates (results not shown).
In addition to t subtelomeric amplification of chr mosome 34, we bserved several structural
variations affecting the telomeric or subtelomeric regions of many chromosomes. Subtelomeric
amplifications are present in chromosomes 8, 17, 19, 22, 26, 27, 31, and 34, although only those
from chromosome 22 and 31 appear to have occurred after exposure to SbIII and were subsequently
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maintained up to 2000 µM. Conversely, chromosome 31 also exhibited a uniform decrease in coverage
in a region spanning 52 kb at one of its ends (Figure 4), suggesting the deletion of this region in
some of the copies of the chromosome. This is the only example of a subtelomeric deletion we found
in this study and it is uniformly present in all the treated samples and the untreated PSC-1 strain.
Although this is not a total deletion, this variation potentially decreases the dosage of at least 20 genes
to half of that for the rest of the genes in this chromosome. Remarkably, one of these is the AQP1
gene (LPMP_310020), which encodes for an aquaglyceroporin that is widely known to be involved in
antimony resistance. As shown in Figure 4, this deletion is not present in the clinical isolates.
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Figure 4. Relatively large subtelomeric deletion on chromosome 31. This deletion is estimated to
be present in approximately half of the copies of this chromosome, spanning a region of 52 kb and
affecting 20 protein-coding genes, including the one encoding aquaglyceroporin AQP1. The deletion is
present in the PSC-1 reference strain even before exposure to SbIII, but it is not apparently present in
clinical isolates BD-02 and RG-01. Except for those used for the isolates, colors in this figure follow the
conventions used in Figure 3. CYP5: cyclophilin 5.
3.3. Variations at the Level of Individual Protein-Coding Genes
In order to identify copy nu ber variations (C Vs) associated ith individual protein-coding
genes, e used a strategy based on the detection of local variations in read depth overlapping
annotated gene models. As expected, we observed a uniform increase in read depth spanning several
protein-coding genes in the Sb-treated samples and the untreated control, possibly associated with
tandem gene arrays (Table S4). Excluding those genes located within the regions reported to be
differentially amplified in the previous section (Figure 3A,B; Figure 4), the vast majority of the genes
found to be locally amplified in the treated samples matched those previously reported for the strain
PSC-1 [23], all with similar estimates of haploid copy number. A relatively small number of genes
showed different copy number estimates at different SbIII concentrations (Table 1), the majority of which
were observed after exposure to the smallest concentration of 50 µM and were apparently maintained
with similar estimates at higher concentrations. With very few exceptions, clinical isolates BD-02 and
RG-01 also exhibited a similar set of amplified genes than the untreated PSC-1 strain (Table S5).
Many of the genes whose estimated copy number appears to have increased after exposure to
SbIII also seem to have a higher copy number in the clinical isolates, when compared to the untreated
PSC-1 strain. These remarkably include genes widely known to be involved in parasite survival
and virulence, such as LPMP_020120 (phosphoglycan-β-1,3-galactosyltransferase), LPMP_080610
(amastin-like protein), LP P_080680 (tuzin), LPMP_090170/LPMP_190790 (autophagy-related protein
8), LPMP_100410/ LPMP_100440 (leishmanolysin), LPMP_130280 (α tubulin), LPMP_330860 (β tubulin),
LPMP_170080 (elongation factor 1-α), LPMP_330370 (heat shock protein 83), and LPMP_331700
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(peptidase M20/M25/M40). However, the number of copies estimated for some of these genes in the
clinical isolates seems to be notably higher than in the treated samples. For instance, the gene encoding
tuzin has an average estimated copy number of 27 in the treated samples and one of 37 in the isolates.
Similarly, the gene coding for elongation factor 1-α appears to have 33 copies on average in the isolates
versus 21 in the treated samples. In contrast, gene LPMP_311770, encoding a ubiquitin-fusion protein,
appears to have fewer copies in the treated samples (27 on average) than in the untreated PSC-1 strain
(32), but a notably higher number of copies in the clinical isolates (50 on average).
Table 1. Protein-coding genes with different haploid copy number estimates among the samples
included in this study 1.
Gene Suspected Function
Estimated Haploid Copy Number
PSC-1
Treated Samples [SbIII] µM
RG-01 BD-02
50 100 200 400 800 1600 2000
LPMP_020120 Phosphoglycan
β-1,3-galactosyltransferase
2 3 3 3 3 3 3 3 4 5
LPMP_040170 Hypothetical protein 10 14 14 14 14 14 13 13 18 14
LPMP_040280 β-fructofuranosidase 3 4 4 4 4 4 4 4 2 5
LPMP_050490 ATPase α subunit 3 4 4 4 4 4 3 3 4 6
LPMP_060560 60S ribosomal protein L23a 3 2 2 2 2 2 2 2 2 2
LPMP_080610 Amastin-like protein 14 19 17 17 17 18 16 16 14 21
LPMP_080680 Tuzin 22 30 27 27 26 28 27 26 39 34
LPMP_080890 Hypothetical protein 2 1 1 1 1 1 1 1 1 1
LPMP_090170 Autophagy-related protein 8 (ATG8) 13 19 20 19 20 21 19 19 20 16
LPMP_100410 GP63, leishmanolysin 9 12 12 11 11 11 10 11 13 10
LPMP_100440 GP63, leishmanolysin 6 8 8 8 8 8 7 7 8 7
LPMP_130280 α-tubulin 19 21 22 22 23 22 22 22 26 24
LPMP_160880 Flagellar calcium-binding protein 3 2 2 2 2 2 2 2 2 2
LPMP_170080 Elongation factor 1-α 15 21 21 21 21 22 20 20 33 34
LPMP_190790 Autophagy-related protein 8 (ATG8) 10 15 15 16 14 16 14 14 11 16
LPMP_311770 Ubiquitin-fusion protein 32 28 27 27 27 28 22 23 51 50
LPMP_330370 Heat shock protein 83 12 14 14 14 14 14 13 13 16 12
LPMP_330860 β-tubulin 34 45 43 43 43 44 41 41 41 34
LPMP_331700 Peptidase M20/M25/M40 12 15 14 15 15 14 14 14 15 12
1 This table does not include the genes located within relatively large regions suspected to be episomic amplifications,
as well as other forms of subtelomeric variations, all of which also have a different gene dosage.
We also used a strategy combining two programs, GATK and SvABA, to detect relatively small
variants such as single nucleotide variants (SNVs) and indels within protein-coding genes. Since the
identification of such variants is technically difficult in regions subjected to different forms of genetic
amplifications, we attempted to introduce the estimated somy for each chromosome as a parameter for
the variant caller. However, SNVs predicted within genes in putative tandem arrays, whose reads
tend to collapse in alignments, were flagged as heterozygotic and were not further considered. We
found four genes harboring at least one SNV or indel that appear to have occurred after exposure to
SbIII, namely, genes LPMP_120520, LPMP_120820, LPMP_323330, and LPMP_340960. All these genes
encode hypothetical proteins of unknown function, except for LPMP_120820, which putatively codes
for an N-ethylmaleimide reductase. The two genes from chromosome 12 have a SNV detected above
50 µM and maintained through all the concentrations subsequently evaluated. However, none of these
SNVs were predicted to have a high impact in the function of the corresponding genes, since they are
both associated with a putative missense mutation. Allele frequencies estimated with GATK for the
SNVs detected in genes LPMP_120520, LPMP_120820, and LPMP_323330 provide additional evidence
for the changes in somy reported for the corresponding chromosomes (Table S6), i.e., frequency for the
two SNVs from chromosome 12 was 0.333, thus suggesting a trisomic state, while allele frequency
for the SNV detected in LPMP_323330 changed from 0.5, the expected frequency for a disomic state,
to 0.333 at 1600 µM.
On the other hand, distribution of small variants in genes LPMP_323330 and LPMP_340960
suggests that these genes may have internal amino acid repeats whose number of copies have varied
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during antimony treatment. Gene LPMP_323330 contains tetratricopeptide (TPR) repeat domains, IQ
short calmodulin domains, and two domains of unknown functions, the latter present in at least two
additional copies in concentrations above 800 µM of SbIII. Gene LPMP_340960 contains a Zinc finger
domain of the CCCH type (Pfam: PF00642) and a repeat of nine units of the trinucleotide CAG, which
is shortened to eight units due to the deletion of one repeated unit in the sample exposed to 2000 µM
of SbIII.
4. Discussion
Leishmania is a kinetoplastid parasite with an extraordinary genomic plasticity. It is now well
accepted that genomic changes occur frequently in this genus, commonly altering the number of copies
of chromosomal regions and genes but maintaining global gene synteny. Since regulation of gene
expression in Leishmania and the kinetoplastids does not appear to occur primarily at the level of
transcription, many of these genomic changes may represent an adaptive advantage for the parasite,
particularly if they alter the number of copies of critical genes to cope with changing environmental
conditions. These forms of genetic amplification can be achieved in several ways, including the
intrachromosomal increase in the number of copies of individual genes to give rise to tandem gene
arrays, the extrachromosomal amplification of relatively larger regions to generate episomal amplicons,
and the increase in somy of entire chromosome leading to aneuploid states that are well tolerated by
the parasite. Here, we used whole genome sequencing (WGS) data to characterize and compare the
genomic variations present in a laboratory-adapted strain of L. panamensis, seven samples derived
from this strain exposed to increasing concentrations of SbIII, as well as two clinical isolates obtained
from patients from two different Panama provinces, both with no sign of treatment failure. The main
difference between strain PSC-1 and the two clinical isolates is that the later were recently isolated
from human patients and have undergone two laboratory passages, while strain PSC-1 was isolated in
1994 and have undergone several passages.
Genomic changes have long been known to be critical for acquisition of resistance against
pentavalent antimonials in Leishmania. Antimony resistance is a multifactorial process that involves
several redundant mechanisms, all of them roughly aimed at inactivating the drug, decreasing its
influx or increasing its efflux [8,31]. In fact, most of the studies addressing this topic in different
Leishmania species have reported changes in the somy of individual chromosomes in strains with the
Sb-resistant phenotype [9,10,13–15]. Here, we not only observed variations in chromosome somy in
the final resistant parasites, but also noticed that these changes occurred actively during acquisition
of resistance. Changes in somy started to occur after exposure to the lowest SbIII concentration
and some of these changes were maintained consistently through all the range of concentrations
studied. Chromosomes 1, 18, and 31 showed a progressive increase in somy at increasingly higher SbIII
concentrations. Chromosome 23 also showed an increase in somy up to 800 µM of SbIII, but the somy
decreased at higher concentration, a finding that may be associated with the occurrence of H-locus
amplifications in samples above 800 µM of SbIII.
H-locus amplification is a type of episomal amplification that has been previously implicated in
the acquisition of the antimony resistant phenotype. Here we observed the amplification of a region of
~53 kb overlapping the location of the original H-locus [32]. Amplification of the original region was
shown to give rise to the so-called H circles, which contain two 30 kb inverted repeats derived from the
amplified locus. The presence of these H circles was initially reported in Leishmania strains resistant to
methotrexate [33,34] and was later implicated in resistance to antimonials [16,18]. Downing et al. [35]
also reported the amplification of this locus in Sb-resistant L. donovani isolates; however, the region
found to be amplified in this study was shorter (13.5 kb) and contained only four genes. Despite the
evident variation in size, all forms of H-locus amplifications contain the MRPA gene encoding an ABC
transporter mediating the incorporation of Sb-thiol complexes into intracellular vesicles [36]. These
vesicles are thought to be involved in a secretory pathway that reduces the intracellular accumulation
of SbIII, which can be considered a form of inactivation by sequestration [37].
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A similar variation in size has been observed in a different type of episomal amplification well
studied in Leishmania, this one associated with a different locus in chromosome 34 and called LD1.
In contrast to H-locus amplifications, LD1 amplicons have not been associated with antimony resistance,
but with an increased fitness for the parasite due to the presence of a gene encoding a biopterin
transporter (BT1). Here, we found evidence for the presence of an LD1 amplicon resembling a linear
minichromosome, previously described for L. braziliensis strain M2903 [22]. This amplicon was found
in our reference strain PSC-1 and it was apparently maintained in this strain after treatment with
SbIII up to a concentration of 100 µM. The loss of this amplicon at higher SbIII concentrations may be
associated with the later occurrence of other amplifications putatively involved in the Sb-resistant
phenotype. Among these, the H-locus amplification and two subtelomeric amplifications found above
100 µM of SbIII, the later respectively located in chromosome 22 (~97 kb, 26 genes) and chromosome
31 (~150 kb, 45 genes). However, further studies are required to find if these amplifications are in
fact associated with antimony resistance or are just stochastic changes, a product of the highly plastic
nature of the Leishmania genome. In fact, Patino et al. [15] recently reported the presence of a ~50 kb
amplification in the subtelomeric region of chromosome 27 of Sb-resistant L. panamensis mutants, which
we did not observe in our treated samples.
We also noticed the deletion of a ~52 kb subtelomeric region of chromosome 31 in both the
treated samples and the untreated strain PSC-1, but not in the clinical isolates. This deletion can be
considered partial, since it appears to affect roughly half of the copies of this chromosome, which
was estimated to be at least tetrasomic in all the samples included in this study. A similar terminal
deletion of chromosome 31 has been previously reported for Sb-resistant mutants of L. major [13]
and L. guyanensis [38]. In all cases, the deleted region contains the AQP1 gene encoding a specific
aquaglyceroporin that imports SbIII into amastigotes [19]. Since the untreated PSC-1 strain has a
notably higher EC50 value than the susceptible clinical isolates, it is likely that even a decrease in
the number of copies of this gene, rather than its total loss or inactivation, may give the parasite an
adaptive advantage in the presence of SbIII.
In addition to changes associated with entire chromosomes or relatively large chromosomal
regions, it is now well known that changes at the level of certain genes are also associated with
the Sb-resistant phenotype. For instance, Monte-Neto et al. [14] reported a higher gene dosage for
the MRPA gene in four Sb-resistant L. guyanensis mutants, but due to tandem amplification of this
gene, rather than the extrachromosomal amplification of the H-locus. This form of intrachromosomal
amplification, leading to tandem gene arrays, have been reported in all Leishmania genomes sequenced
to date, although the set of genes that are amplified can be slightly different. Here, we observed
that the vast majority of the genes that were found to be locally amplified in reference strain PSC-1
maintained their organization in suspected tandem gene arrays after exposure to SbIII, suggesting that
these are long-term or stable amplifications, conserved during evolution regardless of environmental
stress. However, we indeed observed differences in the estimated haploid copy numbers for many
of these genes, the majority of them occurring after exposure to the lowest SbIII concentration of
50 µM. A remarkable case is that of gene LPMP_230230, encoding a type C ABC transporter (ABCC),
which appears to form a tandem gene array within the H-locus amplicons, resembling a form of
“nested” amplification.
Surprisingly, we found notable less genomic variations in the clinical isolates, when compared to
the treated samples and the untreated PSC-1 strain. In these isolates, there is almost no occurrence of
subtelomeric or episomal amplifications and changes in the somy of entire chromosomes (with the
exception of chromosome 31). A reduction in aneuploidy in samples isolated from animal hosts has
been previously reported for other L. donovani species [11,12,39]. The predominant form of genetic
amplification in our clinical isolates appears to be tandem gene arrays, with some genes exhibiting
remarkably higher copy number estimates than the laboratory-adapted samples.
Our findings suggest that the set of genomic amplifications occurring in a Leishmania population
may be balanced by the compromise between availability of precursors required for DNA synthesis
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and the advantage these amplifications may represent for the parasite in terms of fitness, under certain
environmental conditions. For instance, at high SbIII concentrations in vitro, the somy of the already
tetrasomic chromosome 23 was observed to decrease, while the number of copies of the putatively
episomic H-locus amplification increased. Occurrence of these H-locus amplifications also appears
to be associated with the loss of the minichromosome deriving from chromosome 34. In contrast,
this minichromosome, which is thought to give an adaptive advantage related to folate metabolism,
appears to be present in vitro in the reference strain but only in absence or low concentrations of SbIII.
While none of these amplifications were found in the clinical isolates, notably higher numbers of
copies were observed for certain genes widely known to be involved in infection and virulence. These
findings contribute to emphasize the relevance of rapid changes at the DNA level in a pathogenic
parasite with almost no transcriptional regulation of gene expression.
Although the balance between precursor availability and response to environmental stress could
be a potential explanation of changes observed in this study, we do not rule out other possible scenarios.
For instance, it has been shown in other unicellular eukaryotes that large changes in gene dosages
may produce an array of potential problems in cells, including a response similar to those triggered by
environmental stress [40,41] and slower growth and proliferation [42–44]. Additionally, aneuploidy in
eukaryotes may cause metabolic and proteotoxic stress [45]. Also, variations in gene copy number have
been shown to cause a dramatic effect in fitness, as is the case of the β-tubulin gene in Saccharomyces
cerevisiae [46]. Therefore, since many of the genes in amplified regions are of unknown function, it may
be possible that amplification at certain genomic regions may also increase unintended gene activities,
ending up in a reduction of parasite fitness. Then, in an attempt to limit these adverse effects, secondary
or compensatory genomic variations may also occur. More studies will be necessary to establish if
some of the variations observed here in L. panamensis may indeed have a compensatory effect.
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